Nikhil Lalwani serves as the President and Chief Executive Officer of ANI Pharmaceuticals, Inc., a role he has held since 2015. Under his leadership, ANI has experienced significant growth and transformation, evolving into a diversified biopharmaceutical company. Prior to joining ANI, Lalwani held the position of President at Novartis Pharmaceuticals Canada, where he was instrumental in driving the company's strategic direction and operational excellence. His extensive experience in the pharmaceutical industry also includes leadership roles at Novartis in the United States and Latin America, where he honed his skills in business development and market expansion. Lalwani's tenure at ANI has been marked by several key achievements, including the successful acquisition and integration of several businesses that have expanded the company's product portfolio and market reach. Notably, he led the acquisition of rare disease company Sandoz Inc.'s generic portfolio and the subsequent launch of several new products. His strategic vision has been pivotal in positioning ANI as a leader in the development and commercialization of pharmaceuticals, particularly in the areas of controlled substances and oncology. Lalwani's commitment to innovation and patient care has driven the company's efforts to bring high-quality, affordable medications to market. As CEO, Nikhil Lalwani is responsible for overseeing ANI's overall strategy and operations, ensuring that the company continues to grow and meet its objectives. He leads a team focused on advancing the company's mission to improve patient outcomes through the development and delivery of innovative pharmaceutical solutions. Lalwani's leadership style emphasizes collaboration, accountability, and a relentless focus on excellence, qualities that have endeared him to employees, partners, and investors alike. His contributions have not only strengthened ANI's position in the industry but have also set a foundation for sustained future success.